Clinicians can predict which patients with ocular hypertension are most likely to develop primary open-angle glaucoma (POAG) using short-wave automated perimetry, scanning laser polimetry, and confocal laser ophthalmoscopy, as well as the patient’s age, researchers said.
Clinicians will soon have another treatment option for their patients with non-severe primary open-angle glaucoma (POAG). A micro invasive glaucoma surgical (MIGS) device (CyPass Micro-Stent, Alcon) has been approved by the FDA for use in patients with mild-moderate PAOG in conjunction with cataract surgery.
The combination of MICS and MIGS can offer an effective surgical treatment for POAG when the reduction of IOP following cataract surgery alone is not sufficient to reduce a patient’s need for glaucoma therapies.
Selective laser trabeculoplasty is safe and effective for reducing IOP in patients with glaucoma. However, not all patients respond to treatment and its effects are not permanent even in those who respond well.
In this comparison study, IOP reductions were greater with BTFC than with TTFC and patients on this combination were more likely to achieve and maintain low target pressures. Combined BrTFC and DTFC may also be a more appropriate therapeutic choice for IOP lowering than TTFC and BrTFC, respectively.